GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (STU:29TA) » Definitions » Cyclically Adjusted FCF per Share

TherapeuticsMD (STU:29TA) Cyclically Adjusted FCF per Share : €-21.05 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is TherapeuticsMD Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

TherapeuticsMD's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.018. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-21.05 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 22.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 37.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of TherapeuticsMD was 49.30% per year. The lowest was -48.90% per year. And the median was -10.70% per year.

As of today (2024-06-07), TherapeuticsMD's current stock price is €1.86. TherapeuticsMD's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-21.05. TherapeuticsMD's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of TherapeuticsMD was 26.00. The lowest was 0.62. And the median was 1.46.


TherapeuticsMD Cyclically Adjusted FCF per Share Historical Data

The historical data trend for TherapeuticsMD's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Cyclically Adjusted FCF per Share Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -138.86 -40.11 -17.91 -21.60 -21.81

TherapeuticsMD Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.37 -21.80 -21.29 -21.81 -21.05

Competitive Comparison of TherapeuticsMD's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Cyclically Adjusted Price-to-FCF falls into.



TherapeuticsMD Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TherapeuticsMD's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.018/131.7762*131.7762
=-0.018

Current CPI (Mar. 2024) = 131.7762.

TherapeuticsMD Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.579 100.560 -3.380
201409 -2.916 100.428 -3.826
201412 -4.073 99.070 -5.418
201503 -5.423 99.621 -7.173
201506 -6.421 100.684 -8.404
201509 -4.645 100.392 -6.097
201512 -4.401 99.792 -5.812
201603 -4.508 100.470 -5.913
201606 -3.584 101.688 -4.644
201609 -4.305 101.861 -5.569
201612 -3.860 101.863 -4.994
201703 -4.883 102.862 -6.256
201706 -4.028 103.349 -5.136
201709 -3.380 104.136 -4.277
201712 -4.212 104.011 -5.336
201803 -3.711 105.290 -4.645
201806 -4.990 106.317 -6.185
201809 -10.220 106.507 -12.645
201812 -5.275 105.998 -6.558
201903 -7.129 107.251 -8.759
201906 -9.485 108.070 -11.566
201909 -5.180 108.329 -6.301
201912 -12.294 108.420 -14.942
202003 -6.593 108.902 -7.978
202006 -9.202 108.767 -11.149
202009 -5.344 109.815 -6.413
202012 -4.423 109.897 -5.304
202103 -4.695 111.754 -5.536
202106 -2.804 114.631 -3.223
202109 -3.866 115.734 -4.402
202112 -4.249 117.630 -4.760
202203 -1.906 121.301 -2.071
202206 -2.248 125.017 -2.370
202209 1.933 125.227 2.034
202212 2.628 125.222 2.766
202303 -0.833 127.348 -0.862
202306 -0.306 128.729 -0.313
202309 -0.528 129.860 -0.536
202312 -0.412 129.419 -0.420
202403 -0.018 131.776 -0.018

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


TherapeuticsMD  (STU:29TA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of TherapeuticsMD was 26.00. The lowest was 0.62. And the median was 1.46.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


TherapeuticsMD Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (STU:29TA) Business Description

Industry
Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

TherapeuticsMD (STU:29TA) Headlines

No Headlines